USTEKINUMAB
Information current as at: 1 May 2025
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Wezlana
- Pharmaceutical company:
- Amgen Australia Pty Limited
- Condition/indication:
(therapeutic use) -
- Psoriatic arthritis Crohn disease Chronic plaque psoriasis Ulcerative colitis
- PBAC Submission type:
- New PBS listing (Category 3)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – March 2024
- Related medicines:
- --
Progress Details
-
Submission received for: - March 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 22/11/2023 and close 31/01/2024 (see PBS Website)
-
PBAC meeting: - Held on 13/03/2024
-
Lodgement of required documentation: - 31/05/2024
-
Acceptance of complete documentation:
- Not Accepted
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a855
Page last updated: 02 April 2025